Loading...
XNZE
AFT
Market cap193mUSD
Nov 13, Last price  
3.20NZD
Name

AFT Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XNZE:AFT chart
P/E
22.78
P/S
1.32
EPS
0.14
Div Yield, %
1.00%
Shrs. gr., 5y
0.30%
Rev. gr., 5y
17.68%
Revenues
255m
+23.95%
40,363,00048,939,00056,241,00057,670,27069,047,00079,882,00084,872,000105,241,000112,861,000129,834,000155,820,000195,411,000205,494,000254,705,000
Net income
15m
+23.14%
172,000-1,113,000-12,873,0000-18,388,000-12,724,000-2,427,00012,692,0007,782,00019,848,00010,654,00015,609,00011,962,00014,730,000
CFO
-12m
L
-3,970,00066,000-13,105,000-14,429,000-19,062,000-10,904,000-2,493,0009,277,000-2,426,00012,223,0009,004,00025,548,00013,176,000-11,750,000
Dividend
Jun 18, 20250.018 NZD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health categories, including but not limited to allergy relief, cold and flu remedies, digestive health, eye care, first aid essentials, nail and oral care, pain management, skincare solutions, and nutritional supplements. This company was established in 1997 and its main office is located in Auckland, New Zealand.
URL
http://www.aftpharm.com/
IPO date
Dec 22, 2015
Employees
100
Domiciled in
NZ
Incorporated in
NZ

Valuation

Title
NZD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT